Healthcare
Avivagen Inc.(VIVXF)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → Jun 17, 2026
- Market Cap
- —
- Revenue Growth
- -27.5%
- EPS Growth
- +23.4%
- Dividend Yield
- 0.0%
Coverage: 249 bars · Jun 20, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Avivagen Inc. (VIVXF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -27.5%, EPS growth of +23.4%, a dividend yield of 0.0%. What stands out right now is revenue -27.5%, EPS +23.4%, free cash flow +32.4% with operating margin -99.4% and ROIC -916.2%. Valuation is more restrained than many high-expectation growth names at price/sales 0.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VIVXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-27.5% vs +7.6% peer median
Operating Margin
Below sector median
-99.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -27.5% and EPS is at +23.4%, with operating margin around -99.4%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VIVXF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VIVXF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VIVXF and SPY.
Company Overview
Avivagen Inc.
Other OTC
Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.
- Leadership
- G. F. Kym Anthony
- IPO Date
- May 2, 2013
- Employees
- 13
- Street Address
- 100 Sussex Drive
- Mailing
- Ottawa, ON, K1A 0R6
- Region
- Ottawa, ON, CA
- Reporting Currency
- USD
- Investor Line
- +1 613 949 8164
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 0.8
- Price/Book
- —
Growth
- Revenue
- -27.5%
- EPS
- +23.4%
- Free Cash Flow
- +32.4%
Profitability
- Gross Margin
- 42.6%
- Operating Margin
- -99.4%
- Net Margin
- -645.9%
- ROE
- 122.1%
- ROIC
- -916.2%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.61
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.